ClinicalTrials.gg
CompletedNCT05130606Updated Nov 3, 2026

CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing

An interventional study of Culturally Targeted Narrative Video: "Is My Cancer Hereditary? Rosa Visits a Genetic Counselor." and FORCE Fact Sheet in Hereditary Breast and Ovarian Cancer, sponsored by Georgetown University. Completed at 2 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Georgetown University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2021, registered Sep 2021).
Updated Nov 3, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
289
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Hereditary Breast and Ovarian Cancer Syndrome · United States.

Enrollment
7th of 23
289 · median 157
Started
2021
with 1 other
No phase
17 of 35
4 open now
Registered
29th of 35
by date
Lead sponsor
6 of 35
Georgetown University

Among the 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States, this one is the 7th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2021, is one of 17 with no phase, and was the 29th registered.

Hereditary Breast and Ovarian Cancer Syndrome

62 studies on the registry are indexed under Hereditary Breast and Ovarian Cancer Syndrome; 13 are open to participants now.

Browse Hereditary Breast and Ovarian Cancer Syndrome studies →

Open to participants now

7 of the 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Hereditary Breast and Ovarian Cancer Syndrome studies recruiting now, 7 (70%) set no upper age limit and 1 (10%) stops at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a mixed-methods Hybrid Type 1 research design (efficacy study) in which we aim to conduct a two-arm randomized controlled trial and an Implementation Focused Process Evaluation of a culturally-targeted video and referral screening tool.

In this study, the investigators aim to evaluate the efficacy of a culturally targeted video previously developed by the research team vs. a Spanish-language fact sheet from an established group on enhancing genetic counseling and testing uptake and psychosocial outcomes in Latina women at risk for hereditary breast and ovarian cancer.

The investigators will test the video's efficacy while also gathering data on the implementation and future sustainability of using the Risk Screening Tool (RST) and video in community clinics.

Read the detailed description

The investigators previously developed and piloted a culturally targeted narrative video in Spanish to provide HBOC and GCT education to at-risk Latinas. The investigators expanded traditional approaches to address psychosocial barriers through risk messages designed to elicit emotional responses; emotions are often stronger predictors of behavior than cognition. Our video is responsive to Latinas' preferences, targets motivators, and addresses psychosocial barriers identified in our formative research.

In this study, the investigators aim to evaluate the efficacy of our video vs. a fact sheet from an established group on enhancing GCT uptake and psychosocial outcomes on a two-arm randomized controlled trial. The investigators will test the video's efficacy while also gathering data on the implementation and future sustainability of using an adapted Risk Screening Tool (RST) and video in community clinics.

The investigators will partner with community clinics and implement a Risk Screening Tool (RST) at their practice to identify women at risk of HBOC. Community clinic staff (N\~32) will be asked to participate in a pre-implementation and a post-implementation focus group to assess implementation outcomes of integrating HBOC screening practices in their clinic. Through the community clinics, the investigators aim to recruit N\~300 Latina women at risk for HBOC based on their personal or family history of cancer. Latina women at risk for HBOC will be randomized to a Video arm or Fact Sheet Arm. All participants in the randomized controlled trial will be offered genetic counseling and testing.

03

Conditions studied

  • Hereditary Breast and Ovarian Cancer

Keywords

  • Breast cancer
  • Ovarian cancer
  • Hereditary cancer
  • Latinas
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Aim 1 and 2.

  • Self-identify as a Latina woman
  • Be 18 years old or older
  • Be able to provide
  • Be fluent in Spanish
  • Meet NCCN criteria to be considered for genetic cancer risk assessment for HBOC, whether by a personal history of cancer or family history of cancer
  • No previous participation in genetic counseling or testing for hereditary breast and ovarian cancer risk
  • No other family members are participating in this study
  • Have not participated in any previous studies involving interventions about HBOC or GCT

Aim 3.

  • Be 18 years old or older
  • Be fluent in English or Spanish
  • Have a role in the partner community clinic as either a) full-time or part-time employee b) intern c) volunteer

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
289 participants (actual)

Study arms

  • Experimental
    Video Arm

    Culturally Targeted Narrative Video: "Is My Cancer Hereditary? Rosa Visits a Genetic Counselor." Participants in the video arm will be asked to watch an 18-minute video that the research team developed and tested previously about HBOC and genetic services. The video is recorded with Spanish audio and is available with English subtitles.

    Behavioral: Culturally Targeted Narrative Video: "Is My Cancer Hereditary? Rosa Visits a Genetic Counselor."

  • Active comparator
    Fact Sheet Arm

    Participants in the Fact Sheet arm will receive a Fact sheet about HBOC and genetic services and will be asked to read it in their own time. The Fact Sheet is available in English and Spanish.

    Behavioral: FORCE Fact Sheet

Interventions

  • BehavioralCulturally Targeted Narrative Video: "Is My Cancer Hereditary? Rosa Visits a Genetic Counselor."

    Participants randomized to the video arm will receive a link with a password by email or text message to watch the video, depending on participants' preference. Participants without internet access will receive a DVD. Participants will be instructed to watch the video alone with no interruptions. We will ask them not to share the link with others.

  • BehavioralFORCE Fact Sheet

    Participants will receive a PDF of the fact sheet by email, text message, or a printed fact sheet by mail depending on participants' preferences. The fact sheet includes information about genes, breast cancer, risk factors for HBOC, genetic counseling and testing, and resources.

06

What researchers measure

Primary outcomes

  1. Uptake of Genetic Counseling

    Participants will self report whether they attended a genetic counseling session in the four months following their baseline survey. The study team will also have direct access to the genetic counseling company's records.

    Time frame: Change from the baseline survey to four months after baseline

  2. Uptake of Genetic Testing

    Participants will self report whether they completed a genetic test for hereditary cancer in the four months following their baseline survey. The study team will also have direct access to the genetic counseling company's records.

    Time frame: Change from the baseline survey to four months after baseline

Secondary outcomes

  1. Knowledge about HBOC

    9-item Scale from Kasting et al, 2019. The scale has statements to which participants respond True, False, or I don't Know. The scale is scored based on the accuracy of responses. A higher score indicates higher knowledge. Scores range from 0-9.

    Time frame: Change from the baseline to two-week after baseline, and change from two-week follow up survey to four months after baseline

  2. Self-efficacy about attending genetic cancer risk assessment

    Change in self-efficacy about genetic counseling and testing will be measured by specific items from the Theory of Planned Behavior scale (Ajzen, 2002) on a scale from 1-7 -Not at all to 7- Extremely)

    Time frame: Change from the baseline to two-week after baseline

  3. Beliefs and Attitudes about genetic cancer risk assessment

    Changes in beliefs and attitudes about genetic counseling and genetic testing. The outcome will be assessed by 22 items from a scale developed by Sussner, Jandorf, Thompson et al., 2012 in which participants respond to a Likert-type scale from 1 (completely disagree) to 7 (completely agree).

    Time frame: Change from the baseline to two-week after baseline

  4. Subjective norms about genetic cancer risk assessment

    Change in subjective norms about genetic counseling and testing will be measured by specific items from the Theory of Planned Behavior scale (Ajzen, 2002) on a scale from 1-Not at all to 7- Extremely)

    Time frame: Change from the baseline to two-week after baseline

  5. Anticipatory emotions about genetic cancer risk assessment

    Scale items on a 7-point Likert-type response (from 1-strongly disagree to 7-strongly agree).

    Time frame: Change from the baseline to two-week after baseline

  6. Acceptability of the intervention

    Overall acceptability is measured on a 4-item self-reported scale ranging from 1 to 10, where 1 = not at all to 10 = highly

    Time frame: At two weeks after baseline

  7. Feasibility of the intervention

    Proportion of women who have watched/read the video or fact sheet at the two week follow up

    Time frame: At two weeks after baseline

Other outcomes

  1. Feasibility of the Referral Screening Tool

    Qualitative measure captured through semi-structured interviews using the Consolidated Framework for Implementation Research. (e.g., What barriers and facilitators did you experience while implementing the RST?)

    Time frame: Change from the pre-implementation focus groups with community clinics to post implementation focus groups with community clinics (48 months)

  2. Acceptability of the Referral Screening Tool

    Qualitative measure captured through semi-structured interviews using the Consolidated Framework for Implementation Research.

    Time frame: Change from the pre-implementation focus groups with community clinics to post implementation focus groups with community clinics (48 months)

  3. Adoption of the Referral Screening Tool

    Qualitative measure captured through semi-structured interviews using the Consolidated Framework for Implementation Research.

    Time frame: At the post implementation focus groups with community clinics adoption over the previous 48 months will be assessed

  4. Sustainability of the Referral Screening Tool

    Qualitative measure captured through semi-structured interviews using the Consolidated Framework for Implementation Research.

    Time frame: At the post implementation focus groups with community clinics sustainability of the screener based on their experience during the previous 48 months will be assessed

07

Study locations

2 sites
  • Georgetown Lombardi Comprehensive Cancer Center
    Washington D.C., District of Columbia 20007, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23284, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Jun 2026, 60 months.

Of 23 interventional studies with no phase under Hereditary Breast and Ovarian Cancer Syndrome, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 31. This study's 60 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Dec 2025 → Jun 2026 and completion Dec 2025 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2021
First posted
Nov 23, 2021
StartActual
Jun 1, 2021
Primary completionActual
Jun 30, 2026was Dec 2025
CompletionActual
Jun 30, 2026was Dec 2025
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 3, 2026
Primary completion
Dec 31, 2025→Jun 30, 2026 (actual)
Nov 3, 2026
Study completion
Dec 31, 2025→Jun 30, 2026 (actual)
Nov 3, 2026
Enrollment
332 (estimated)→289 (actual)
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Recruiting→Completed
    Primary completion Dec 31, 2025→Jun 30, 2026 (now actual)
    Study completion Dec 31, 2025→Jun 30, 2026 (now actual)
    Enrollment 332 (estimated)→289 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05130606
Responsible party
Sponsor
First posted
Nov 23, 2021
Start date
Jun 1, 2021
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026
Last update
Nov 3, 2026

Study contacts

Alejandra Hurtado de Mendoza, Ph.D
principal investigator · Georgetown Lombardi Comprehensive Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion